Protherics PLC Announces Holding(s) in Company
October 27 2008 - 2:21PM
Marketwired
Protherics PLC
Notification of Major Interests in Shares
London, UK; Brentwood, TN, US: 27 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that on 27
October 2008, in accordance with the Transparency Obligations
Directive, a notification of interest in the ordinary share capital of
the Company was received from AXA Investment Managers UK Limited on
behalf of AXA S.A. and its Group Companies ("AXA"). Details of the
interest notified are set out below.
The notification follows an increase in the Company's issued ordinary
share capital following the conversion of all outstanding six per cent.
unsecured convertible loan notes 2010 of Protherics, as further
described in the announcement made jointly by Protherics and BTG plc on
18 September 2008.
1. Reason for the notification (please tick
the appropriate box or boxes)
An acquisition or disposal of voting rights
An acquisition or disposal of financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
An event changing the breakdown of voting rights
Other (please specify): variation in issued X
share capital
2. Full name of person(s) subject to the AXA S.A., 25 Avenue
notification obligation: Matignon, 75008 Paris and
its group of companies.
3. Full name of shareholder(s) (if different
from 2.):
4. Date of the transaction (and date on which 26 October 2008
the threshold is crossed or reached if
different):
5. Date on which issuer notified: 27 October 2008
6. Threshold(s) that is/are crossed or 12%
reached:
7. Notified details:
A: Voting rights attached to shares
Class/ Situation previous to Resulting situation after the triggering
type of the Triggering transaction
shares transaction
if
possible Number of Number of Number of Number of voting % of voting
using Shares Voting shares rights rights
the ISIN Rights
CODE
Direct Direct Indirect Direct Indi-
-rect
0702920 42,026,712 42,026,712 1,041,666 1,041,666 40,985,046 0.30%11.70%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting rights that % of
financial date Conversion may be acquired if the voting
instrument Period/ instrument is exercised/ rights
Date converted.
Total (A+B)
Number of voting rights % of voting rights
42,026,712 11.99%
8. Chain of controlled undertakings through which the voting rights and
/or the financial instruments are effectively held, if applicable :
Name of Company/Fund Number of % of issued share
Shares capital
AXA 716,666 0.20451
Direct
AXA Framlington 40,985,046 11.69573
Indirect
AXA IM UK 325,000 0.09274
Direct
Total Direct 1,041,666 0.29726
Total Indirect 40,985,046 11.69573
TOTAL 42,026,712 11.99298
Proxy Voting:
9. Name of the proxy holder:
10. Number of voting rights proxy holder will
cease to hold:
11. Date on which proxy holder will cease to hold
voting rights:
12. Additional information:
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Contacts: RNS Customer Services 0044-207797-4400 Email Contact
http://www.rns.com
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024
